Syndax Pharmaceuticals (SNDX) said Thursday that an experimental combination treatment achieved a composite complete remission rate of 71% in patients with certain forms of relapsed or treatment-resistant acute myeloid leukemia in a phase 1/2 trial.

The company said the treatment, which combines Revuforj, decitabine/cedazuridine and venetoclax, produced an overall response rate of 88% among 42 patients whose disease had returned or failed to respond to previous treatments.

About 45% of patients went on to receive a stem cell transplant after treatment, the company added.

After a median follow-up of 22 months, patients who achieved remission remained in response for a median of 10.5 months, the company said.